Claims
- 1. A method of co-administering to a mammal a compound of category (1) defined as a compound that has inhibitory effect on the CP450RAI enzyme of the mammal and
a compound of category (2) defined as a compound selected from the group consisting of vitamin A, a derivative of vitamin A having vitamin A like biological activity, retinoic acid and a retinoid, to prevent, treat or delay the onset of a disease or condition that is prevented, treated or the onset of which is delayed by adminstration of a retinoid compound or by the mammal's naturally occurring retinoic acid.
- 2. A method in accordance with claim 1 where the compound of category (1) and the compound of category (2) are co-administered to a human being.
- 3. A method in accordance with claim 2 where the compound of category (1) and the compound of category (2) are co-administered in a single formulation.
- 4. A method in accordance with claim 2 the compound of category (1) and the compound of category (2) are co-administered in two separate formulations.
- 5. A method in accordance with claim 2 where the compound of category (1) and the compound of category (2) are both administered topically.
- 6. A method in accordance with claim 5 where the compound of category (1) and the compound of category (2) are administered to prevent, treat or delay the onset of photodamage to the skin, acne or psoriasis.
- 7. A method in accordance with claim 1 where the compound of category (2) is vitamin A.
- 8. A method in accordance with claim 2 where the compound of category (2) is vitamin A.
- 9. A method in accordance with claim 6 where the compound of category (2) is vitamin A.
- 10. A method in accordance with claim 1 where the compound of category (1) has the formula
- 11. A method in accordance with claim 10 where the compound of category (2) is vitamin A.
- 12. A method in accordance with claim 10 where in the formula R2 is H, F, or methyl, R3 is methyl and R is H or a pharmaceutically acceptable salt thereof, or CH2—O—COCH3.
- 13. A method in accordance with claim 12 where the compound of category (2) is vitamin A.
- 14. A method in accordance with claim 10 where the compound of category (1) is
- 15. A method in accordance with claim 14 where the compound of category (2) is vitamin A.
- 16. A method in accordance with claim 1 where the compound of category (1) has the formula
- 17. A method in accordance with claim 16 where the compound of category (2) is vitamin A.
- 18. A method in accordance with claim 16 where the compound has the formula
- 19. A method in accordance with claim 18 where the compound has the formula
- 20. A method in accordance with claim 19 where the compound of category (2) is vitamin A.
- 21. A method in accordance with claim 16 where the compound of category (2) has the formula
- 22. A method in accordance with claim 21 where the compound has the formula
- 23. A method in accordance with claim 22 where the compound of category (2) is vitamin A.
- 24. A method in accordance with claim 1 where the compound of category (1) and the compound of category (2) are administered topically in a formulation or formulations containing between 0.1 and 10.0 milligrams per milliliter of formulation of the compound of category (1) and between 0.01 mg to 10 mg per milliliter of the formulation of the compound of category (2).
- 25. A method in accordance with claim 24 where the compound of category (1) and the compound of category (2) are administered topically in a formulation or formulations containing between 1.0 and 5.0 milligrams per milliliter of formulation of the compound of category (1) and between 1.0 mg to 5.0 mg per milliliter of the formulation of the compound of category (2).
- 26. A method in accordance with claim 1 where the compound of category (1) and the compound of category (2) are administered systemically in a daily dose containing between 0.01 and 5.0 mg per kg body weight of the mammal of the compound of category (1) and between 0.01 mg to 5.0 mg per kg body weight of the mammal of the compound of category (2).
- 27. A method in accordance with claim 26 where the compound of category (1) and the compound of category (2) are administered systemically in a daily dose containing between 0.1 and 2.5 mg per kg body weight of the mammal of the compound of category (1) and between 0.1 mg to 2.5 mg per kg body weight of the mammal of the compound of category (2).
- 28. A pharmaceutical composition for administration to a mammal containing a pharmaceutically acceptable excipient and an effective dose of a compound of category (1) defined as a compound that has inhibitory effect on the CP450RAI enzyme of the mammal and
a compound of category (2) defined as a compound selected from the group consisting of vitamin A, a derivative of vitamin A having vitamin A like biological activity, reinoic acid and a retinoid, to prevent, treat or delay the onset of a disease or condition that is prevented, treated or the onset of which is delayed by adminstration of a retinoid compound or by the mammal's naturally occurring retinoic acid.
- 29. A pharmaceutical composition in accordance with claim 28 adapted for topical administration to a human being.
- 30. A pharmaceutical composition in accordance with claim 29 where the compound of category (2) is vitamin A.
- 31. A pharmaceutical composition in accordance with claim 28 adapted for systemic administration to a human being.
- 32. A pharmaceutical composition in accordance with claim 31 where the compound of category (2) is vitamin A.
- 33. A pharmaceutical composition for administration to a mammal containing a pharmaceutically acceptable excipient and an effective dose of a compound of the formula
- 34. A pharmaceutical composition in accordance with claim 33 adapted for topical administration to a human being.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application is a continuation in part of application Ser. No. 10/389,071 filed on Mar. 14, 2003 which is a continuation-in-part of application Ser. No. 10/100,638 filed on Mar. 19, 2002.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10389071 |
Mar 2003 |
US |
Child |
10656715 |
Sep 2003 |
US |
Parent |
10100638 |
Mar 2002 |
US |
Child |
10389071 |
Mar 2003 |
US |